Universal Technical Institute, Inc. (UTI)

Q: What's priced into Universal Technical Institute, Inc. (UTI) stock?

UTI trades at a 2.17-times premium to peers, which points to an expensive valuation. The evidence labels that premium justified, but the expectations gap is slightly negative and model confidence is low, so the degree of optimism already reflected is uncertain.

Q: What does the Universal Technical Institute, Inc. (UTI) outlook hinge on?

The thesis depends on enrollment growth continuing and strategic spending translating into stronger results over time. A further guidance cut or continued weakening in job growth could weigh on the outlook, while stronger results and guidance from sector peers could support sector momentum.

NYSEConsumer StaplesEducation & Training ServicesSnapshot 2026-10-23

$21.85+0.88%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Universal Technical Institute, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	233.61M
EPS	—	0.145
Annual ending 2027-09-30
Revenue	—	968.88M
EPS	—	0.719
Annual ending 2028-09-30
Revenue	—	1.07B
EPS	—	1.183

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
EPS around $0.77 for fiscal 2026	Earnings per share are expected near $0.77 this year.	Broken	EPS falls below $0.77 in FY26	Diluted EPS: $0.04 per share FY2026-Q3; GAAP. Published target: >= $0.77. Target period is not explicitly aligned with this observation. Source published Aug 6, 20260.04 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q3 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 2b980fa8-3dee-4d95-954d-efbce9e5e10b. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
New student starts between 31,500 and 33,000 for fiscal 2026	New student starts target is about 33,000.	Broken	New student starts fall below 31,500 in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. New student starts increased from 5,721 in 2025-Q3 to 6,342 in 2026-Q3 (+10.9%), with similar double-digit growth in prior quarters. Management highlighted new campuses and programs as key drivers. The trajectory shows delivering consistent enrollment growth aligned with stated goals. Delivery assessment Oct 24, 2026
Revenue between $905 million and $915 million for fiscal 2026	A primary condition in Universal Technical Institute, Inc.'s published investment case. The stated target is >= $905 million and <= $915 million.	Broken	Revenue falls below $905 million in FY26	Revenue: $218.907M FY2026-Q3; GAAP. Published target: >= $905 million and <= $915 million. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026218,907,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q3 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 2b980fa8-3dee-4d95-954d-efbce9e5e10b. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-09-30 · fmp

FY2028 EPS: comparable history unavailable.

FY2028 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-10-01	Unavailable	Unavailable	2 / 2
2026-10-02	Unavailable	Unavailable	2 / 2
2026-10-03	Unavailable	Unavailable	2 / 2
2026-10-04	Unavailable	Unavailable	2 / 2
2026-10-05	Unavailable	Unavailable	2 / 2
2026-10-06	Unavailable	Unavailable	2 / 2
2026-10-07	Unavailable	Unavailable	2 / 2
2026-10-08	Unavailable	Unavailable	2 / 2
2026-10-09	Unavailable	Unavailable	2 / 2
2026-10-10	Unavailable	Unavailable	2 / 2
2026-10-11	Unavailable	Unavailable	2 / 2
2026-10-12	Unavailable	Unavailable	2 / 2
2026-10-13	Unavailable	Unavailable	2 / 2
2026-10-14	Unavailable	Unavailable	2 / 2
2026-10-15	Unavailable	Unavailable	2 / 2
2026-10-16	Unavailable	Unavailable	2 / 2
2026-10-17	Unavailable	Unavailable	2 / 2
2026-10-18	Unavailable	Unavailable	2 / 2
2026-10-19	Unavailable	Unavailable	2 / 2
2026-10-20	Unavailable	Unavailable	2 / 2
2026-10-21	Unavailable	Unavailable	2 / 2
2026-10-22	Unavailable	Unavailable	2 / 2
2026-10-23	Unavailable	Unavailable	2 / 2
2026-10-24	Unavailable	Unavailable	2 / 2

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	6	0	0
2026-06-01	6	0	0
2026-07-01	6	0	0
2026-08-01	6	0	0
2026-09-01	6	0	0
2026-10-01	6	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

EPS around $0.77 for fiscal 2026Published status: Broken
New student starts between 31,500 and 33,000 for fiscal 2026Published status: Broken
Revenue between $905 million and $915 million for fiscal 2026Published status: Broken

Next proof point

Nov 18, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.7%Typical daily move · historical

Downside history

-63.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Universal Technical Institute, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

UTI is a growth-and-execution story, with a longer-term case tied to higher student starts and active enrollment. The thesis is in a watch state: revenue and enrollment have grown, but recent performance has lagged its industry cohort and confidence is medium.

What's priced into Universal Technical Institute, Inc.

UTI trades at a 2.17-times premium to peers, which points to an expensive valuation. The evidence labels that premium justified, but the expectations gap is slightly negative and model confidence is low, so the degree of optimism already reflected is uncertain.

What the fundamentals likely do

Over the multi-year view, management’s North Star strategy has supported growth: revenue rose 7.2%, new student starts rose 10.9%, and average active students rose 5.8% year over year. Near term, strategic spending is weighing on earnings, while fiscal 2026 revenue and diluted EPS guidance have been cut; the latest quarter was also missed despite an earlier earnings-beat event.

What Universal Technical Institute, Inc. hinges on

The thesis depends on enrollment growth continuing and strategic spending translating into stronger results over time. A further guidance cut or continued weakening in job growth could weigh on the outlook, while stronger results and guidance from sector peers could support sector momentum.

Bottom line

For the next 1 to 3 years, UTI has visible enrollment growth but also high risk, recent guidance reductions, and pressure on adjusted EBITDA. The long-term thesis hinges on execution improving enough to support the premium valuation. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.